Published in PLoS One on September 11, 2017
Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res (2003) 103.76
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol (2002) 10.95
STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res (2014) 10.79
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol (2006) 8.53
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer (2004) 5.63
CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res (2010) 5.42
Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer (2009) 5.06
CHD5 is a tumor suppressor at human 1p36. Cell (2007) 4.90
Histone deacetylases and cancer. Oncogene (2007) 4.30
Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol (2004) 4.15
Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res (2009) 3.66
Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst (2000) 3.63
Transcriptional regulation and its misregulation in disease. Cell (2013) 2.92
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol (2011) 2.87
Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68
Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer (2007) 2.65
Non-Hodgkin lymphoma. Lancet (2012) 2.59
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol (2012) 2.56
Mechanisms of cancer-related fatigue. Oncologist (2007) 2.25
Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA (2015) 2.20
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia (2008) 2.07
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol (2014) 2.06
Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol Cell Biol (2003) 2.03
Mast cells and inflammation. Biochim Biophys Acta (2010) 1.91
Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis (2012) 1.84
Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program (2011) 1.80
Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol (2003) 1.78
Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. Proc Natl Acad Sci U S A (2006) 1.64
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res (2011) 1.49
Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene (2007) 1.49
Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal (2013) 1.45
Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor. Neurology (2012) 1.41
Wnt signaling inside the nucleus. Cancer Sci (2008) 1.40
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics (2013) 1.38
The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt. beta-catenin signaling cascade. J Biol Chem (2004) 1.37
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Chemotherapy-induced thrombosis. Thromb Res (2006) 1.34
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr (2014) 1.30
Phage display: selecting straws instead of a needle from a haystack. Molecules (2011) 1.30
PLCG1 mutations in cutaneous T-cell lymphomas. Blood (2014) 1.30
Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol (2014) 1.29
Histamine receptors and cancer pharmacology. Br J Pharmacol (2010) 1.28
Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol (2010) 1.27
Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets (2010) 1.22
Chromatin signatures of cancer. Genes Dev (2015) 1.20
G9a, a multipotent regulator of gene expression. Epigenetics (2012) 1.20
Sequencing the functional antibody repertoire--diagnostic and therapeutic discovery. Nat Rev Rheumatol (2014) 1.20
Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha1 subunit in small-cell lung cancer cells. Oncogene (2003) 1.15
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist (2015) 1.13
Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules (2014) 1.12
Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene (2001) 1.12
Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother (2013) 1.11
Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res (2012) 1.10
The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab (2013) 1.09
Acute and chronic cardiovascular effects of doxorubicin in the dog: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol (1980) 1.09
Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene (2006) 1.08
Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem (2010) 1.07
Current trends in large cell lymphoma. Leukemia (2003) 1.06
Coordination of adjacent domains mediates TACC3-ch-TOG-clathrin assembly and mitotic spindle binding. J Cell Biol (2013) 1.06
Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer (2012) 1.06
TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia (2004) 1.05
SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death Differ (2010) 1.04
CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer (2011) 1.01
Deregulation of Wnt/β-catenin signaling through genetic or epigenetic alterations in human neuroendocrine tumors. Carcinogenesis (2013) 1.01
Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages. Cancer (2013) 1.00
Integrin-linked kinase at a glance. J Cell Sci (2012) 1.00
Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol (2013) 0.99
Role of CHD5 in human cancers: 10 years later. Cancer Res (2014) 0.99
Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Front Pharmacol (2013) 0.99
The role of BCL11B in hematological malignancy. Exp Hematol Oncol (2012) 0.97
Topoisomerase IIα in chromosome instability and personalized cancer therapy. Oncogene (2014) 0.97
Glutamate signaling in benign and malignant disorders: current status, future perspectives, and therapeutic implications. Int J Biol Sci (2013) 0.96
Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes. Oncogene (2001) 0.96
BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. Mol Cancer (2013) 0.96
Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer (2010) 0.96
Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancer. Pharmacol Rev (2014) 0.96
Wnt/β-catenin Signaling in Normal and Cancer Stem Cells. Cancers (Basel) (2011) 0.94
Control of adipogenesis by the SUMO-specific protease SENP2. Mol Cell Biol (2010) 0.93
Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. Gastroenterology (2013) 0.93
TGF-beta signaling in colon cancer cells. World J Surg (2005) 0.93
Targeting the WNT Signaling Pathway in Cancer Therapeutics. Oncologist (2015) 0.92
Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer. Breast Cancer Res (2012) 0.90
The emerging role of CaMKII in cancer. Oncotarget (2015) 0.90
Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma. BMC Cancer (2011) 0.90
AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Lett (2014) 0.88
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol (2003) 0.88
Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer (2010) 0.88
Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. J Clin Oncol (2015) 0.88
Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond. Anticancer Agents Med Chem (2011) 0.88
The attenuating effect of memantine on staurosporine-, salsolinol- and doxorubicin-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int (2007) 0.87
Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies. Biochem Res Int (2012) 0.86
FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801. BMC Cancer (2013) 0.86
Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol (2008) 0.86
Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation. Oncotarget (2015) 0.85
Early gene expression changes in spinal cord from SOD1(G93A) Amyotrophic Lateral Sclerosis animal model. Front Cell Neurosci (2013) 0.85
Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem Pharmacol (2005) 0.85
The EBMT Risk Score in the Presence of Graft Versus Host Disease in Allogeneic Stem Cell Transplantation in Adult Acute Myelogenous Leukemia: A Multistate Model for Competing Risks. Int J Hematol Oncol Stem Cell Res (2014) 0.78
The Effect of GVHD on Long-term Outcomes after Peripheral Blood Allogeneic Stem Cell Transplantation from an HLA-identical Sibling in Adult Acute Lymphocytic Leukemia: A Landmark Analysis Approach in Competing Risks. Int J Hematol Oncol Stem Cell Res (2014) 0.78
Effect of Peptone Feeding on Transient Gene Expression Process in CHO DG44. Avicenna J Med Biotechnol (2014) 0.77
The Role of Different Supplements in Expression Level of Monoclonal Antibody against Human CD20. Avicenna J Med Biotechnol (2013) 0.77
Evaluating the efficiency of phiC31 integrase-mediated monoclonal antibody expression in CHO cells. Biotechnol Prog (2016) 0.76
Effects of Peptone Supplementation in Different Culture Media on Growth, Metabolic Pathway and Productivity of CHO DG44 Cells; a New Insight into Amino Acid Profiles. Iran Biomed J (2015) 0.76
JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden. Int J Hematol Oncol Stem Cell Res (2016) 0.75
Emotional, Social and Occupational Adjustment among Oncology Nurses. Int J Hematol Oncol Stem Cell Res (2016) 0.75
Designed Amino Acid Feed in Improvement of Production and Quality Targets of a Therapeutic Monoclonal Antibody. PLoS One (2015) 0.75
Enhanced truncated-t-PA (CT-b) expression in high-cell-density fed-batch cultures of Pichia pastoris through optimization of a mixed feeding strategy by response surface methodology. Bioprocess Biosyst Eng (2016) 0.75
Comparison of 60 and 80 mg/m(2) of daunorubicin in induction therapy of acute myeloid leukaemia. Hematol Oncol (2015) 0.75
Evaluating the efficiency of CHEF and CMV promoter with IRES and Furin/2A linker sequences for monoclonal antibody expression in CHO cells. PLoS One (2017) 0.75
How Do Donor-Recipient CMV Serostatus and Post-Hematopoietic Stem Cell Transplantation CMV Reactivation Affect Outcomes in Acute Leukemia Patients? Int J Hematol Oncol Stem Cell Res (2017) 0.75
A Systems Medicine Approach Reveals Disordered Immune System and Lipid Metabolism in Multiple Sclerosis Patients. Clin Exp Immunol (2017) 0.75
Monoclonal antibodies expression improvement in CHO cells by PiggyBac transposition regarding vectors ratios and design. PLoS One (2017) 0.75
MALDI-MS: a Rapid and Reliable Method for Drug-to-Antibody Ratio Determination of Antibody-Drug Conjugates Iran Biomed J (2019) 0.75
PhiC31 integrase can improve the efficiency of different construct designs for monoclonal antibody expression in CHO cells. Protein Expr Purif (2017) 0.75
Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets. Sci Rep (2017) 0.75